Autres langues Harvard Bioscience, Inc.

Actions

HBIO

US4169062043

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq 22:00:00 04/08/2026 Varia. 5j. Varia. 1 janv.
6,310 USD 0,00% Graphique intraday de Harvard Bioscience, Inc. +6,59% -5,65%

Autres langues

28/07 Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
12/05 Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05 Harvard Bioscience : Q1 2026 Harvard Bioscience, Inc. Earnings Conference Call
12/05 Harvard Bioscience: Q1 Earnings Snapshot
12/05 Harvard Bioscience Announces First Quarter 2026 Financial Results
12/05 Harvard Bioscience, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reaffirms Earnings Guidance for the Full Year 2026
07/05 Harvard Bioscience to Participate in Upcoming Investor Conferences
28/04 Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
12/03 Harvard Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
12/03 Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026
12/03 Harvard Bioscience: Q4 Earnings Snapshot
12/03 Harvard Bioscience : Q4 2025 Harvard Bioscience, Inc. Earnings Conference Call
12/03 Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
10/03 Harvard Bioscience, Inc. Appoints Mark Frost as Treasurer, Effective March 6, 2026
10/03 Harvard Bioscience, Inc. Appoints Mark Frost as Chief Financial Officer, Effective March 6, 2026
06/03 Harvard Bioscience Declares Reverse Stock Split
06/03 Harvard Bioscience announces reverse stock split
06/03 Harvard Bioscience Announces Reverse Stock Split
03/03 Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
26/02 Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
10/02 Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
29/01 Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
29/01 Harvard Bioscience, Inc. Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
17/12 Harvard Bioscience, Inc. Appoints Bill Snider as Member of Class Iii of the Board and as Member of Compensation Committee, Effective December 17, 2025
17/12 Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
Aucun résultat pour cette recherche